NeuBase Therapeutics Financials

NeuBase Therapeutics Stock Summary

NeuBase Therapeutics competes with Immix Biopharma, Cns Pharmaceuticals, Sonnet Biotherapeutics, ZyVersa Therapeutics, and Biomx. NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Neu Base operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people.

NeuBase Therapeutics Key Financial Ratios

NeuBase Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining NeuBase Therapeutics's current stock value. Our valuation model uses many indicators to compare NeuBase Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NeuBase Therapeutics competition to find correlations between indicators driving NeuBase Therapeutics's intrinsic value. More Info.NeuBase Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value NeuBase Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.